Artrya Ltd
ASX:AYA
Artrya Ltd
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.
Revenue Inflection: Artrya began generating scalable revenue this quarter, validating its technology and market adoption, with $60,000 in customer receipts from three foundational U.S. customers now under contract.
Financial Strength: The company completed an $80 million capital raise and ended the quarter with $76.5 million in cash and liquid assets and no debt, supporting a shift from R&D to commercial execution.
Key Contracts Secured: Three foundational U.S. partners (Northeast Georgia, Cone Health, Tanner Health) have all signed multi-year contracts for Artrya’s products, establishing a base for future revenue growth.
SAPPHIRE Study Progress: Six high-volume U.S. health systems joined the SAPPHIRE study, representing a combined 400,000 CCTA scans per year and providing a significant long-term commercial opportunity.
FDA Submission Update: Submission for the Salix Coronary Flow module is now targeted for clearance by end of June 2026, with expanded studies to ensure a robust application, though management is not concerned about the timeline shift.
Operational Expansion: U.S.-based customer success and support teams have been built to enhance onboarding and integration for new customers.
Positive Customer Feedback: Early users report dramatic efficiency gains, with scan reading times dropping from 25 minutes to about 5 minutes using Artrya’s platform.
Insurance Coverage Momentum: Over 85% of U.S. insured lives now have coverage for the Plaque module as more major insurers come onboard.
